Date: 28.12.2011
Researchers from the Perelman School of Medicine at the University of Pennsylvania are in the midst of testing a personalized, dendritic cell vaccine in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer - a group of patients who typically have few treatment options.
Now, they have shown they can shorten the time to manufacture this type of anti-cancer vaccine, which reduces costs of manufacturing the treatment while still yielding powerful dendritic cells that may be beneficial for these and a variety of other tumor types. The data is published in the December issue of PLoS ONE.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Biotechnology Books - Huge database of biotechnology books
Biotechnology links - Useful biotech links for you
Researchers develop light-activated protein superglue for fast and precise control of cells and tissues
Plant non-steroidal anti-inflammatory leaves immune system intact